Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

We recommend the following alternatives

W IP         H
REACTIVITY SENSITIVITY MW (kDa) SOURCE
32, 38 Rabbit

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

XAF1 Antibody recognizes endogenous levels of total XAF1 protein. Unknown background bands are observed at 45, 70, and 85 kDa.


Species predicted to react based on 100% sequence homology: Monkey

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val210 of human XAF1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1) is a zinc finger protein that antagonizes the anti-apoptotic activity of XIAP (1,2). XIAP, a member of the inhibitor of apoptosis (IAP) family, inhibits apoptosis by direct inhibition of caspases (3; reviewed in 4). XAF1 is widely expressed in normal tissues, with highest levels in the heart and ovary, but is mostly reduced in cancer lines (1,2). Expression of XAF1 can be induced by interferons via Stat transcriptional activity (5-7). The levels of XAF1 have been shown to be inversely correlated with p53, and p53 is directly responsible for inhibiting XAF1 transcription (8,9). A number of studies have shown that XAF1 can function as a tumor suppressor protein, and decreased levels of XAF1 are found in a variety of different cancers (10-13). Research studies suggest that expression of XAF1 may be a prognostic biomarker for some cancers (14-16).


1.  Fong, W.G. et al. (2000) Genomics 70, 113-22.

2.  Liston, P. et al. (2001) Nat Cell Biol 3, 128-33.

3.  Goyal, L. (2001) Cell 104, 805-8.

4.  Leaman, D.W. et al. (2002) J Biol Chem 277, 28504-11.

5.  Deveraux, Q.L. et al. (1997) Nature 388, 300-4.

6.  Sun, Y. et al. (2008) Cancer Lett 260, 62-71.

7.  Bai, Y. et al. (2008) J Biol Chem 283, 6832-42.

8.  Zhang, W. et al. (2010) Int J Oncol 36, 1031-7.

9.  Zou, B. et al. (2012) Mol Carcinog 51, 422-32.

10.  Byun, D.S. et al. (2003) Cancer Res 63, 7068-75.

11.  Ng, K.C. et al. (2004) J Invest Dermatol 123, 1127-34.

12.  Ma, T.L. et al. (2005) Chin J Dig Dis 6, 10-4.

13.  Zou, B. et al. (2006) Gastroenterology 131, 1835-43.

14.  Huang, J. et al. (2010) Cancer Sci 101, 559-67.

15.  Chen, Y.B. et al. (2011) Chin Med J (Engl) 124, 3238-43.

16.  Wang, Y. et al. (2012) Regul Pept 178, 36-42.


Entrez-Gene Id 54739
Swiss-Prot Acc. Q6GPH4


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.